Source comparison
CJC-1295 no DAC & Ipamorelin: Protocol Comparison
GH Release Mechanism GHRH receptor agonist. Amplifies natural pulses Ghrelin receptor agonist. Triggers independent release Dual-pathway stimulation with synergistic effect Combined protocol produces 30–50% higher IGF-1 elevation than either peptide alone Cort
This comparison does not assign a generated winner or score.
- GH Release Mechanism
- GHRH receptor agonist. Amplifies natural pulses
- Ghrelin receptor agonist. Triggers independent release
- Dual-pathway stimulation with synergistic effect
- Combined protocol produces 30–50% higher IGF-1 elevation than either peptide alone
- Cortisol/Prolactin Impact
- Minimal at therapeutic doses
- No measurable elevation
- Ipamorelin's selectivity makes the combination safe for long-term use
- Injection Frequency
- 1–2x daily
- 2–3x daily for sustained effect
- 1–2x daily (same timing for both peptides)
- Once-daily dosing (bedtime) is sufficient for most women over 40; twice-daily adds marginal benefit
- Typical Dosage Range
- 100–200mcg per injection
- 200–300mcg per injection
- 100–200mcg each per injection
- Starting at lower end (100mcg each) and titrating based on side effects is standard
- Cost per Month (Estimated)
- $80–$120
- $90–$140
- $150–$220
- Combined protocol is more cost-effective than using higher doses of a single peptide
- Reconstitution Stability
- 28 days refrigerated
- 28 days refrigerated (store together or separately)
- Both peptides can be mixed in the same syringe immediately before injection